Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Stein, Anthony  [Clear All Filters]
2024
Ladbury C, Sanchez J, Chowdhury A, Palmer J, Liu A, Stein A, Htut M, Farol L, Cai J-L, Somlo G, et al. Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma. Am J Clin Oncol. 2024.
2023
Mei M, Palmer J, Tsai NNi-Chun, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai J-L, Htut M, et al. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Clin Lymphoma Myeloma Leuk. 2023.
2022
Khaldoyanidi SK, Hindoyan A, Stein A, Subklewe M. Leukemic Stem Cells as a Target for Eliminating Acute Myeloid Leukemia: Gaps in Translational Research. Crit Rev Oncol Hematol. 2022:103710.
Ladbury C, Armenian S, Bosworth A, He T, F Wong L, Dandapani S, Han C, Liu A, Malki MAl, Rosenthal J, et al. Risk of subsequent malignant neoplasms following hematopoietic stem cell transplantation with total body irradiation or total marrow irradiation: insights from early follow-up. Transplant Cell Ther. 2022.
2019
Nakamura R, Gendzekhadze K, Palmer J, Tsai N-C, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, Stein A. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. Leuk Res. 2019;87:106230.